Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
PCI-24781
Cat No.
CEI-0340
Description
PCI-24781
Alias
CRA-02478
CAS No.
783355-60-2
Molecular Weight
397.42
Purity
>99%
Storage
2 years at -20 centigrade
Synonyms
CRA-02478
Targets
HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
Molecular Formula
C21H23N3O5
Solubility
No
In vitro
PCI-24781 (CRA-024781) can inhibit HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC10 with Ki of 7 nM, 19 nM, 8.2 nM, 17 nM, 280 nM, 24 nM. PCI-24781 can inhibit multidrug-resistant sarcoma cell lines in dose-dependent accumulation of acetylated histone, p21 and poly(ADP-ribose)polymerase (PARP) cleavage products. PCI-24781 can inhibit sarcoma cell lines with IC50 of 0.43 to 2.7 nM. PCI-24781 reverses drug resistance in all four multidrug-resistant sarcoma cell lines.
In vivo
PCI-24781 [50 mg/kg/day] and control solutions were administered to BK5.erbB2 mice for 4 weeks. Treatment of BK5.erbB2 mice with PCI-24781 for 1 month prevented 79% of GBCa cases from progression and showed a clinical effect in 47% of cases. Treatment with PCI-24781 resulted in decreased expression of Muc4, an intramembrane ligand for ErbB2, in BTC cells. PCI-24781 had more effects on growth inhibition of BTC cells than SAHA. PCI-24781 effectively inhibited the growth of gemcitabine-resistant cells.
Download
Download Datasheet